Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome

This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to

Trial Details

NCT ID
NCT07182526
Phase
PHASE2
Sponsor
Al-Mustansiriyah University
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Quercetin
  • Alpha Lipoic Acid 600 MG Oral Tablet
  • MetFORMIN 500 Mg Oral Tablet
Locations (sample)
  • Baghdad, Karkh, Iraq|33.34058,44.40088

Key Eligibility Criteria

  • • Newly diagnosed patients should be at reproductive aged from 18-40 years.
  • Patients diagnosed with presence of micro polycystic ovaries at ultrasound.
  • Oligomenorrhea with inter-menstrual intervals longer than 35 days.
  • Clinical or biochemical signs of hyperandrogenism (acne, hirsutism).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →